Veradigm receives expected delisting notice from nasdaq

Chicago--(business wire)-- #healthit--veradigm inc. (nasdaq: mdrx), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from the nasdaq stock market llc (“nasdaq”) indicating that the nasdaq hearings panel (the “panel”) has determined to delist the common stock of the company from nasdaq (the “decision”). the decision indicates that the company remains noncompliant with nasdaq listing rule 5250(c)(1) and nasdaq listing rule 56.
MDRX Ratings Summary
MDRX Quant Ranking